article Open AccessTop 1% cited

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

The Lancet Oncology · 2020 · Vol. 21(10) · pp. 1353–1365

Aurélien Marabelle✉(Institut Gustave Roussy)Marwan Fakih(City of Hope)Juanita Lopez(Royal Marsden NHS Foundation Trust)Manisha H. Shah(The Ohio State University)Ronnie Shapira‐Frommer(Sheba Medical Center)Kazuhiko Nakagawa(Kindai University)Hyun Cheol Chung(Yonsei University)Hedy L. Kindler(University of Chicago)José A. López-Martín(Research Institute Hospital 12 de Octubre)Wilson H. Miller(Jewish General Hospital)Antoîne Italiano(Institut Bergonié)Steven Kao(Chris O’Brien Lifehouse)Sarina A. Piha‐Paul(The University of Texas MD Anderson Cancer Center)Jean‐Pierre Delord(Institut Claudius Regaud)Robert R. McWilliams(Mayo Clinic in Arizona)David Fabrizio(Foundation Medicine (United States))Deepti Aurora-Garg(Merck & Co., Inc., Rahway, NJ, USA (United States))Lei Xu(Merck & Co., Inc., Rahway, NJ, USA (United States))Fan Jin(Merck & Co., Inc., Rahway, NJ, USA (United States))Kevin Norwood(Merck & Co., Inc., Rahway, NJ, USA (United States))Yung‐Jue Bang(Seoul National University)

View via DOI Publisher page

Cancer Immunotherapy and Biomarkers Lung Cancer Treatments and Mutations Cancer Genomics and DiagnosticsMedicinePembrolizumabInternal medicineResponse Evaluation Criteria in Solid TumorsOncologyCohortMesotheliomaBiomarkerClinical endpointProspective cohort study

MeSH terms

Antineoplastic Agents, ImmunologicalAgedFemaleHumansImmunotherapyMaleMiddle AgedMutationNeoplasmsProspective StudiesBiomarkers, TumorSurvival AnalysisAntibodies, Monoclonal, HumanizedDrug-Related Side Effects and Adverse ReactionsResponse Evaluation Criteria in Solid Tumors

Citations

2,424

FWCI

119.41

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types